Altogether, focusing on the tumor suppressor role of FOXO1, most of the anticancer drugs that affect FOXO1 in glioma increase its expression, except EMAP-II and Progesterone, which their efficacy is dose or/and time-dependent. This evidence concerns the gene FOXO1 and glioma.